Evaluation of the cytochrome P450-mediated drug interaction profile of olorofim
Antimicrobial Agents and Chemotherapy · 2026
DOI: 10.1128/aac.01745-25 ↗Kurz gefasst
Klinische Studie (Phase I) in der Zeitschrift Antimicrobial Agents and Chemotherapy, 2026. Verfasst von Karen Cornelissen und 8 weiteren Autor:innen. Beteiligte Einrichtung: F2G Ltd, Nether Alderley, Macclesfield, United Kingdom. Hauptthemen laut MEDLINE: Antifungal Agents, Cytochrome P-450 Enzyme System, Piperazines, Pyrimidines. Die Arbeit wurde bisher 2-mal zitiert (Crossref) und nennt 25 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).
Abstract (Originalsprache)
Olorofim is a novel oral antifungal agent which selectively inhibits the fungal enzyme dihydroorotate dehydrogenase found in molds including Aspergillus , Scedosporium , Lomentospora , and Scopulariopsis and in dimorphic fungi such as Coccidioides . Based on in vitro studies, clinical pharmacology, and pharmacokinetic (PK) data from the Phase 2b FORMULA study (F901318/0032) as well as physiologically based PK (PBPK) modeling of drug interactions, the drug’s CYP-mediated interactions are now well understood. Olorofim is mainly metabolized by cytochrome P450 (CYP) CYP3A4, with minor contributions from CYP2C8 and CYP2C9. In vitro studies found that it inhibits CYP3A4, weakly inhibits CYP2D6 and CYP2C8, and weakly induces CYP1A2 and CYP2B6. Phase I studies confirm it is predominantly cleared by CYP3A4 and weakly inhibits CYP3A4. In the Phase 2b FORMULA study, co-administered sensitive CYP3A4 substrates required limited dose reductions when using olorofim. When used with strong CYP3A4 inhibitors, dual moderate inhibitors like fluconazole, or CYP3A4 inducers, dose adjustments were needed for olorofim. Physiologically based PK (PBPK) modeling predicted moderate effects with CYP3A4 inhibitors or inducers and negligible effects with weak CYP3A4 inhibitors or strong inhibitors of CYP2D6, CYP2C8, and CYP2C9. Overall, the drug’s interaction profile is predictable and manageable, making it a suitable candidate drug to use in treating patients with invasive fungal disease (IFD), who often require polypharmacy. CLINICAL TRIALS This study is registered with ClinicalTrials.gov as NCT02680808 , NCT02730442 , NCT02737371 , NCT04171739 , NCT03340597 , and NCT03583164 .
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- F2G Ltd, Nether Alderley, Macclesfield, United Kingdom.
- Cyprotex Discovery Ltd, Macclesfield, United Kingdom.
- Certara UK Ltd, Sheffield, United Kingdom.
- Department of Hematology, University Hospitals Leuven, Leuven, Belgium.
- Centre for Infectious Diseases and Microbiology Laboratory Services, Department of Infectious Diseases, Institute for Clinical Pathology and Medical Research, New South Wales Health Pathology, Westmead Hospital, The Uni…
- Radboud University Medical Centre, Nijmegen, the Netherlands.
ORCID-Profile: Karen Cornelissen, Roger Brüggemann
Zitieren
APA
Cornelissen, K., Rex, J. H., Zinzi, D., Law, D., Upcott Gill, R., Jones, H. M., Maertens, J., Chen, S. C. A., & Brüggemann, R. (2026). Evaluation of the cytochrome P450-mediated drug interaction profile of olorofim. Antimicrobial Agents and Chemotherapy. https://doi.org/10.1128/aac.01745-25
Vancouver
Cornelissen K, Rex JH, Zinzi D, Law D, Upcott Gill R, Jones HM, et al. Evaluation of the cytochrome P450-mediated drug interaction profile of olorofim. Antimicrobial Agents and Chemotherapy. 2026. doi:10.1128/aac.01745-25
BibTeX
@article{Cornelissen2026,
author = {Cornelissen, Karen and Rex, John H and Zinzi, Daniela and Law, Derek and Upcott Gill, Rachel and Jones, Hannah M and Maertens, Johan and Chen, Sharon C-A and Brüggemann, Roger},
title = {Evaluation of the cytochrome P450-mediated drug interaction profile of olorofim},
journal = {Antimicrobial Agents and Chemotherapy},
year = {2026},
doi = {10.1128/aac.01745-25}
}
EUVIMED